PIK3CA and neoplasm: Nevertheless, the high prevalence of PIK3CA alterations alone means that a nearly a quarter of MBC patients could be treated with a matched targeted therapy, even accounting for those that could not have a metastatic sample sequenced as there was a high concordance rate (69% concordance) with the primary tumour.